OKYO Pharma Limited (OKYO) Income Statement
OKYO FY2026 at a glance
Fiscal year ended March 31, 2026 · U.S. dollarsOKYO revenue and net income
OKYO growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
OKYO quarterly EPS vs estimates
OKYO Pharma beat the analyst EPS estimate in 4 of the last 6 quarters.
OKYO income statement
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of revenue | $6.7M | $2,563 | $7.5M |
| Gross profit | −$6.7M | −$2,563 | −$7.5M |
| Research & development | $1.8M | $2.3M | $8.2M |
| Total operating expenses | $1.8M | $7.2M | $8.2M |
| Operating income | −$8.5M | −$7.2M | −$15.7M |
| Interest income | $32,098 | $5,473 | $0 |
| Interest expense | $473,935 | $883,647 | $1.1M |
| Income before taxes | −$8.9M | −$8.0M | −$16.8M |
| Income taxes | $7,987 | −$3.3M | $22,416 |
| Net income | −$8.9M | −$4.7M | −$16.8M |
| EBITDA | −$8.5M | −$7.1M | −$15.7M |
| EPS (diluted) | −$0.06 | −$0.17 | −$0.55 |
| Jun '26 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $935 | $885 | $1,289 | $1,289 | $1,857 | $1,274 | $562 | $3,370 | $1,685 | $2,076 | $2,067 |
| Gross profit | −$935 | −$885 | −$1,289 | −$1,289 | −$1,857 | −$1,274 | −$561 | −$3,370 | −$1,685 | −$2,076 | −$2,067 |
| Research & development | $1.9M | $44,050 | $38,371 | $38,371 | $19 | $2.2M | $1,107 | $3,642 | $1,821 | $4.6M | $2,300 |
| Total operating expenses | $6.4M | $2.8M | $4.2M | $4.2M | $19 | $3.0M | $1,107 | $3,642 | $1,821 | $8.7M | $2,300 |
| Operating income | −$6.4M | −$2.8M | −$4.2M | −$4.2M | $1,669 | −$3.0M | −$1,669 | −$7,012 | −$3,507 | −$8.7M | −$4,367 |
| Interest expense | $357,537 | $84,580 | $119,790 | $125,263 | — | $758,384 | — | $1,052 | — | — | — |
| Income before taxes | −$6.4M | −$2.6M | −$3.9M | −$3.9M | $2,048 | −$4.1M | −$2,048 | −$8,064 | −$4,034 | −$8.7M | −$4,367 |
| Income taxes | $7,935 | $52 | −$1.8M | −$1.8M | $708 | −$1.4M | −$708 | $60 | $30 | $82,830 | $41 |
| Net income | −$6.4M | −$2.6M | −$2.0M | −$2.0M | −$1,013 | −$2.7M | −$1,339 | −$8,124 | −$4,004 | −$8.8M | −$4,409 |
| EBITDA | −$6.4M | −$2.8M | −$3.8M | −$3.8M | −$1,875 | −$2.7M | −$1,669 | −$7,010 | −$3,506 | −$8.7M | −$4,366 |
| EPS (diluted) | — | — | −$0.06 | — | −$0.08 | — | −$0.09 | — | −$0.10 | −$0.11 | −$0.34 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in OKYO's financial statements (latest annual report filed July 20, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
OKYO financial results
OKYO Pharma reported no revenue in fiscal year 2026 (ended March 31, 2026). It had a net loss of $8.9 million. Diluted earnings per share came to −$0.06.
See the OKYO stock overview for the latest quote and news, or the OKYO chart for price history and technical indicators.
OKYO income statement FAQ
Does OKYO Pharma have revenue?
OKYO Pharma reported no revenue for fiscal year 2026, which ended on March 31, 2026.
Is OKYO Pharma profitable?
No. OKYO Pharma reported a net loss of $8.9 million in fiscal 2026.
How much does OKYO Pharma spend on research and development?
OKYO Pharma spent $1.8 million on research and development in fiscal 2026.
What are OKYO Pharma's earnings per share?
OKYO Pharma earned $-0.06 per diluted share in fiscal 2026, compared with $-0.17 a year earlier.
When does OKYO Pharma's fiscal year end?
OKYO Pharma's fiscal year ends in March. The latest annual report covers the year ended March 31, 2026 and was filed on July 20, 2026.